The importance of making a good first impression in the classroom
Researchers examine how medical students evaluate professors
2010-12-11
(Press-News.org) MAYWOOD, Ill. -- A study of how medical students evaluate their professors is illustrating the critical importance of making a good first impression.
Students in a physiology course at Loyola University Chicago Stritch School of Medicine were asked to evaluate 16 professors who lectured during the course. Students had the option of evaluating each professor concurrently during the course, or waiting until the course ended. Students were allowed to change their minds before the evaluations were finalized at the end of the course.
The study, published in the December, 2010 issue of the journal Advances in Physiology Education, included 144 students. Twenty six percent filled out evaluations during the course and 65 percent waited until the course ended. Nine percent did not submit evaluations.
The scores professors received on early evaluations were markedly similar to the scores they received on evaluations made after the course ended. (In statistical terms, the correlation was .91.) And students rarely changed their minds about professors -- only 3 percent of evaluations were revised before the evaluations were finalized.
"Students tended not to change their scores and comments, regardless of the time they submitted their evaluations," researchers wrote. "Hence, first impressions appear to be important."
For decades, students in colleges and graduate schools have been evaluating their professors. Faculty promotion and tenure decisions are based in part on these evaluations.
"The first lecture a faculty member gives to a class really sets the impression," said John A. McNulty, PhD, first author of the study. "The professor is either going to click with the student's learning style, or not."
At Loyola's Stritch School of Medicine, students are asked to rate how well professors communicate, relate course content to learning objectives and add to the student's understanding. Professors are rated on a scale of 1 to 5, with 1 the worst and 5 the best. Students also can write comments.
In the most recent evaluations, the average score for basic science faculty was 4.2, and the average score for clinical faculty (physicians) was 4.38.
"We have a really good faculty," McNulty said. "The distribution of scores is skewed toward the high end."
INFORMATION:
McNulty is a professor in the Department of Cell and Molecular Physiology. Co-authors of the study are Dr. Gregory Gruener, professor in the Department of Neurology; Dr. Arcot Chandrasekhar, professor in the Department of Medicine; Dr. Baltazar Espiritu, associate professor in the Department of Medicine; Amy Hoyt, manager of information technologies for Loyola University Health System, and David Ensminger, clinical assistant professor in the School of Education at Loyola University Chicago.
END
ELSE PRESS RELEASES FROM THIS DATE:
2010-12-11
LEBANON, NH - Kathy Niedzwiecki of Pelham, NH, and Ken Crowder of St. Louis are experiencing renewed life and health thanks to the generosity of two living kidney donors.
Cathy Richard of Henniker, NH, had planned to donate to her sister-in-law, Ms. Niedzwiecki, and Rebecca Burkes of St. Louis had intended to be a living donor for her fiancé, Mr. Crowder – only to find that both were medically incompatible with their intended recipient. But in the first paired donation arranged through a national pilot program of the Organ Procurement and Transplantation Network (OPTN), ...
2010-12-11
SAN ANTONIO — A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2-positive breast cancers, according to data presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12. Full results were presented at the symposium during a press briefing on Dec. 10, 2010, at 8:00 a.m. CT.
Reporters who cannot attend in person can participate using the following call-in information:
U.S. and Canada: (888) 282-7404
International: (706) 679-5207
Access Code: ...
2010-12-11
SAN ANTONIO — Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.
"We had a primary goal to compare the standard anti-HER2 neoadjuvant combination of chemotherapy, trastuzumab, with the new combination of chemotherapy and lapatinib," said Michael Untch, M.D., head of the multidisciplinary breast cancer department at Helios Clinic ...
2010-12-11
SAN ANTONIO — The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere neoadjuvant trial.
Details of these study results were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.
"The findings establish that the addition of pertuzumab to trastuzumab and the chemotherapy drug docetaxel has an impressive rate of tumor eradication (46 percent), which is 50 percent more than achieved with docetaxel and trastuzumab, ...
2010-12-11
SAN ANTONIO — The presence of one to four circulating tumor cells (CTCs) in the blood of early-stage breast cancer patients almost doubled patient's risk of cancer relapse and death, and five or more CTCs increased recurrence by 400 percent and death by 300 percent, according to Phase III results of the SUCCESS trial. These cells were found in patients after surgery but before chemotherapy treatment.
Results of this study were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12, 2010, and demonstrate the value of CTCs in early breast ...
2010-12-11
SAN ANTONIO — A high level of circulating tumor cells (CTCs) — cells that have detached from a tumor and are circulating in the body through the blood — are an independent prognostic marker in metastatic breast cancer as first-line therapy. In addition, persistence of high CTC level during therapy was found to be an early marker of poor outcome.
"This is the largest, prospective series validating the prognostic value of CTCs in first-line chemotherapy metastatic breast cancer, independently from serum tumor markers for overall survival," said Jean-Yves Pierga, M.D., Ph.D., ...
2010-12-11
SAN ANTONIO — For patients with breast cancer and bone metastases, denosumab delayed skeletal-related side effects five months longer compared to those on zoledronic acid, according to results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.
"The average life expectancy of patients with metastatic breast cancer is approximately 2.5 years, so if you can prolong the time without a skeletal-related event by five months, you are substantially benefiting the patient," said Alison T. Stopeck, M.D., associate professor of medicine ...
2010-12-11
SAN ANTONIO — Metastatic breast cancer patients who had circulating tumor cells (CTCs) in their blood before or after high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation had poor outcomes, according to researchers from the University of Texas MD Anderson Cancer Center.
Patients with CTCs in their blood before chemotherapy treatment had reduced survival and those with these cells in their blood after the stem cell transplant recurred faster and died earlier. These findings were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer ...
2010-12-11
SAN ANTONIO — Results of the GeparQuinto study, randomized Phase III efficacy data on the use of bevacizumab plus chemotherapy to treat women with early breast cancer will be presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.
Gunter von Minckwitz, M.D., Ph.D., managing director of the German Breast Group, and colleagues are conducting final analyses on efficacy data from this study, which will detail the early treatment of more than 1,900 patients with HER2-negative breast cancer treated with chemotherapy with or without bevacizumab.
"So far, ...
2010-12-11
Bees can see colours but they perceive the world differently to us, including variations in hue that we cannot ourselves distinguish.
Researchers at Queen Mary, University of London and Imperial College London have developed FReD – the Floral Reflectance Database – which holds data on what colours flowers appear to be, to bees. The development of the catalogue, which has involved a collaborative effort between researchers at two Schools at Queen Mary is reported in the journal PLoS ONE.
The work addresses the existing issue that records of flower colours do not take ...
LAST 30 PRESS RELEASES:
[Press-News.org] The importance of making a good first impression in the classroom
Researchers examine how medical students evaluate professors